Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Case study: nefazodone for juvenile mood disorders

T E Wilens1, T J Spencer, J Biederman

  • 1Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Boston, USA.

Journal of the American Academy of Child and Adolescent Psychiatry
|April 1, 1997
PubMed
Summary

Nefazodone shows promise for treating juvenile mood disorders, with 56% of children experiencing significant improvement. This antidepressant was well-tolerated in a small study of treatment-resistant youth.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Precision weighting of cortical unsigned prediction error signals benefits learning, is mediated by dopamine, and is impaired in psychosis.

Molecular psychiatry·2020
Same author

Precision weighting of cortical unsigned prediction error signals benefits learning, is mediated by dopamine, and is impaired in psychosis.

Molecular psychiatry·2020
Same author

Comorbidity of bipolar I disorder and conduct disorder: a familial risk analysis.

Acta psychiatrica Scandinavica·2019
Same author

Model-Based Approach for Optimizing Study Design and Clinical Drug Performances of Extended-Release Formulations of Methylphenidate for the Treatment of ADHD.

Clinical pharmacology and therapeutics·2017
Same author

Diagnostic utility of brain activity flow patterns analysis in attention deficit hyperactivity disorder.

Psychological medicine·2017
Same author

Can subsyndromal manifestations of major depression be identified in children at risk?

Acta psychiatrica Scandinavica·2016

Area of Science:

  • Psychiatry
  • Pediatric Medicine
  • Pharmacology

Background:

  • Juvenile mood disorders are increasingly recognized, yet effective medication options remain limited.
  • Nefazodone, a novel antidepressant, has not been previously studied in pediatric populations.
  • This study explores nefazodone's efficacy in treatment-refractory children and adolescents with mood disorders.

Observation:

  • Seven children and adolescents (mean age 12.4 years) with diagnosed mood disorders were treated with nefazodone.
  • Treatment duration averaged 13 weeks, with a mean daily dose of 357 mg.
  • Participants had complex conditions, often with multiple prior medication failures and comorbidities.

Findings:

  • 56% of participants showed significant improvement in depressive symptoms, as assessed by the Clinical Global Impression scale.

Related Experiment Videos

  • Two of four children with bipolar depression responded well, while two experienced mild manic activation.
  • Nefazodone was generally well-tolerated, with adverse effects reported in only three subjects.

    • Implications:

    • Nefazodone may represent a viable treatment option for pediatric mood disorders, particularly in cases resistant to other therapies.
    • The observed tolerability suggests a favorable safety profile in this population.
    • Further rigorous, controlled clinical trials are necessary to confirm these preliminary findings and establish definitive treatment guidelines.